A practical reference on nootropic: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Analog of an ACTH fragment |
| Amino acid length | Seven residues | Met-Glu-His-Phe-Pro-Gly-Pro |
| Origin | Moscow, 1980s | Institute of Molecular Genetics |
| Approved regions | Russia and some neighboring states | Not cleared in Western markets |
| Common trade names | Multiple national brands | Sold as a nasal formulation |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
==== Acquired abnormalities ==== Allergic and vasomotor rhinitis – inflammations of the mucous membrane of the nose caused by an allergen, and caused by circulatory and nervous system disorders. Autoimmune system diseases Bites – animal and human Burns – caused by chemicals, electricity, friction, heat, light, and radiation. Connective-tissue diseases Inflammatory conditions Nasal fractures Naso-orbito-ethmoidal fractures – damages to the nose and the eye-sockets; and damage to the bones and the walls of the nasal cavity; it is the ethmoid bone that separates the brain from the nose. Neoplasms – malignant and benign tumors Septal hematoma – a mass of (usually) clotted blood in the septum Toxins – chemical damages caused by inspired substances – e.g. powdered cocaine, aerosol antihistamine medications, et cetera. Traumatic deformities caused by blunt trauma, penetrating trauma, and blast trauma. Venereal infection – e.g., syphilis
=== Cargo === In 2025, Hohhot Baita International Airport handled 60,200 tons of cargo and mail, surpassing the 60,000‑ton mark for the first time, an annual increase of 1.8%. In December alone, throughput reached 7,977 tons, setting a new historical record. Over the year, the airport transported 6,181 tons of fresh meat products, accounting for 10% of total cargo volume, while cold‑chain veterinary pharmaceuticals reached 570 tons, a 30% increase from the previous year.
The method was tested on 96% spirit vodka. In this method, melted wax (stearic acid) is stirred, and the alcoholic drink is poured in. The solution dissipates and becomes drops containing alcohol and wax. The drops that solidify constitute alcohol powder.
Sources: en.wikipedia.org
=== Basic tools === The chemoproteomic toolkit is anchored by liquid chromatography-tandem mass spectrometry (LC-MS/MS or LC-MS) based quantitative proteomics, which allows for the near complete identification and relative quantification of complex proteomes in biological samples. In addition to proteomic analysis, the detection of post-translational modifications, like phosphorylation, glycosylation, acetylation, and recently ubiquitination, which give insight into the functional state of a cell, is also possible. The vast majority of proteomic studies are analyzed using high-resolution orbitrap mass spectrometers and samples are processed using a generalizable workflow. A standard procedure begins with sample lysis, in which proteins are extracted into a denaturing buffer containing salts, an agent that reduces disulfide bonds, such as dithiothreitol, and an alkylating agent that caps thiol groups, such as iodoacetamide. Denatured proteins are proteolysed, often with trypsin, and then separated from other mixture components prior to analysis via LC-MS/MS. For more accurate quantification, different samples can be reacted with isobaric tandem mass tags (TMTs), a form of chemical barcode that allows for sample multiplexing, and then pooled.
Fractures and offsets in a single monazite crystal have been observed mimicking bookshelf faulting in a larger-scale fracturing event. The fractured grain is dated 1375 Ma, indicating that the large-scale displacement happened after this date. Moreover, new monazite may later grow and fill up the space created by the fracture, enclosing the time constraint completely. For example, if the new monazite is dated at 1200 Ma, the displacement probably occurred between 1375 and 1200 Ma.
== History == Inhibition of angiogenesis including VEGFR-2 inhibitors has been of much interest and research in recent decades because angiogenesis is required for tumors to grow beyond a diameter of 1–2 mm. Many small molecular drugs and biological macromolecules targeting VEGFRs or blocking signal transduction of VEGF/VEGFR have been approved for clinical use or entered clinical trials. In 2004 the monoclonal antibody bevacizumab became the first VEGFR inhibitor to be approved for cancer therapy. The first small molecular VEGFR-2 inhibitor to be approved was sunitinib in 2006.
Sources: en.wikipedia.org
== Organizations == Calvin Klein (fashion house), a fashion company CH. Karnchang, a Thai contractor and construction firm Chowking, a Filipino fast food chain Colombo Kings, a team participating in Lanka Premier League CK Hutchison Holdings, a multinational conglomerate headquartered in Hong Kong Bloods, a US-based street gang, from the nickname "Crip Killer" Circle K, an international chain of convenience stores
Rhodesian authorities actively promoted immigration and reproduction of whites to boost their numbers while encouraging family planning for blacks to curtail their numbers. They hoped that by altering the demographic content of the territory enough they could have a stronger position from which to petition the British government for more autonomy.
=== Historical === In 1888, the French botanist Gaston Bonnier demonstrated early experimental evidence for lichen symbiosis through his work with X. parietina (then called Parmelia parietina). He reported creating artificial lichen thalli by replacing the organism's natural algal partner (Protococcus viridis) with different algae species, including Protococcus botryoides and the filamentous reddish alga Trentepohlia abietina. While his methods foreshadowed modern microbiological techniques and represented a significant step for the time, modern assessments note critical limitations. His algal sources were not truly isolated (coming from other lichen thalli), and his "synthesized lichens" only vaguely resembled natural specimens, showing fungal hyphae surrounding algal cells but lacking true lichen morphology. In 1967, Richardson conducted early transplant experiments with X. parietina that helped establish methods for studying lichen adaptability. Using a novel technique of attaching lichen thalli to new substrates with resin glue, the study achieved a 96% survival rate in transplanted specimens. When coastal specimens (var. ectanea) were moved to farm roofs in Oxford, they showed significant morphological changes within 18 months, including increased lobe width from 0.8 mm to 2.4 mm. The study also demonstrated that parietin production could adapt to local conditions within six months, with transplanted specimens eventually matching the pigment levels of native populations.
In order to avoid continuous activation of receptors on the post-synaptic or target cell, neurotransmitters must be removed from the synaptic cleft. Neurotransmitters are removed through one of three mechanisms:
Sources: en.wikipedia.org
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.
It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.
Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.